Consensus on the treatment of pancreatic cancer in Spain

Manuel Hidalgo, Albert Abad, Enrique Aranda, Luis Díez, Jaime Feliu, Carlos Gómez, Antonio Irigoyen, Rafael López, Fernando Rivera, Carmen Rubio, Javier Sastre, Josep Tabernero, Eduardo Díaz-Rubio

Research output: Contribution to journalArticle

Abstract

Pancreatic cancer (PC) represents one of the greatest oncological challenges of our century, due to its high mortality and incidence. A group of Spanish experts in PC treatment reviewed data available on different therapeutic combinations and established consensus on what would be the best strategy in PC management, depending on the stage of the disease. Surgery with complete resection may produce 5-year survival rates of 18-24%, but definitive control is still precarious. In the absence of consensus, the best evidence suggests that adjuvant chemotherapy with gemcitabine for 6 months using the CONKO-001 regime is the treatment of choice after resection of PC for patients with acceptable functional status. This group recommends chemoradiotherapy (CT-RT) in patients with factors for poor loco-regional prognosis. However, chemotherapy is an option for the treatment of locally advanced PC in patients with good general status and in the absence of metastatic disease the recommended treatment is CT-RT followed by gemcitabine-based chemotherapy. A period of chemotherapy followed by consolidation CT-RT may be appropriate, as it allows selection of patients with locally advanced disease who may benefit most from combined treatment. Erlotinib combined with gemcitabine shows significant survival improvement in PC and must be considered an option in the first-line treatment of advanced and metastatic PC. The gemcitabine-erlotinib combination is proposed as the standard treatment for metastatic PC in patients with PS≥2. In patients with PS

Original languageEnglish (US)
Pages (from-to)290-301
Number of pages12
JournalClinical and Translational Oncology
Volume11
Issue number5
DOIs
StatePublished - May 2009
Externally publishedYes

Fingerprint

gemcitabine
Pancreatic Neoplasms
Spain
Therapeutics
Consolidation Chemotherapy
Drug Therapy
Status Epilepticus
Chemoradiotherapy
Adjuvant Chemotherapy
Patient Selection
Survival Rate
Survival
Mortality
Incidence

Keywords

  • Consensus document
  • Epidermal growth factor receptor inhibitor
  • Erlotinib
  • Pancreatic cancer
  • Spain

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Hidalgo, M., Abad, A., Aranda, E., Díez, L., Feliu, J., Gómez, C., ... Díaz-Rubio, E. (2009). Consensus on the treatment of pancreatic cancer in Spain. Clinical and Translational Oncology, 11(5), 290-301. https://doi.org/10.1007/s12094-009-0357-3

Consensus on the treatment of pancreatic cancer in Spain. / Hidalgo, Manuel; Abad, Albert; Aranda, Enrique; Díez, Luis; Feliu, Jaime; Gómez, Carlos; Irigoyen, Antonio; López, Rafael; Rivera, Fernando; Rubio, Carmen; Sastre, Javier; Tabernero, Josep; Díaz-Rubio, Eduardo.

In: Clinical and Translational Oncology, Vol. 11, No. 5, 05.2009, p. 290-301.

Research output: Contribution to journalArticle

Hidalgo, M, Abad, A, Aranda, E, Díez, L, Feliu, J, Gómez, C, Irigoyen, A, López, R, Rivera, F, Rubio, C, Sastre, J, Tabernero, J & Díaz-Rubio, E 2009, 'Consensus on the treatment of pancreatic cancer in Spain', Clinical and Translational Oncology, vol. 11, no. 5, pp. 290-301. https://doi.org/10.1007/s12094-009-0357-3
Hidalgo M, Abad A, Aranda E, Díez L, Feliu J, Gómez C et al. Consensus on the treatment of pancreatic cancer in Spain. Clinical and Translational Oncology. 2009 May;11(5):290-301. https://doi.org/10.1007/s12094-009-0357-3
Hidalgo, Manuel ; Abad, Albert ; Aranda, Enrique ; Díez, Luis ; Feliu, Jaime ; Gómez, Carlos ; Irigoyen, Antonio ; López, Rafael ; Rivera, Fernando ; Rubio, Carmen ; Sastre, Javier ; Tabernero, Josep ; Díaz-Rubio, Eduardo. / Consensus on the treatment of pancreatic cancer in Spain. In: Clinical and Translational Oncology. 2009 ; Vol. 11, No. 5. pp. 290-301.
@article{3ac1c97e53794d849975e10572deaeec,
title = "Consensus on the treatment of pancreatic cancer in Spain",
abstract = "Pancreatic cancer (PC) represents one of the greatest oncological challenges of our century, due to its high mortality and incidence. A group of Spanish experts in PC treatment reviewed data available on different therapeutic combinations and established consensus on what would be the best strategy in PC management, depending on the stage of the disease. Surgery with complete resection may produce 5-year survival rates of 18-24{\%}, but definitive control is still precarious. In the absence of consensus, the best evidence suggests that adjuvant chemotherapy with gemcitabine for 6 months using the CONKO-001 regime is the treatment of choice after resection of PC for patients with acceptable functional status. This group recommends chemoradiotherapy (CT-RT) in patients with factors for poor loco-regional prognosis. However, chemotherapy is an option for the treatment of locally advanced PC in patients with good general status and in the absence of metastatic disease the recommended treatment is CT-RT followed by gemcitabine-based chemotherapy. A period of chemotherapy followed by consolidation CT-RT may be appropriate, as it allows selection of patients with locally advanced disease who may benefit most from combined treatment. Erlotinib combined with gemcitabine shows significant survival improvement in PC and must be considered an option in the first-line treatment of advanced and metastatic PC. The gemcitabine-erlotinib combination is proposed as the standard treatment for metastatic PC in patients with PS≥2. In patients with PS",
keywords = "Consensus document, Epidermal growth factor receptor inhibitor, Erlotinib, Pancreatic cancer, Spain",
author = "Manuel Hidalgo and Albert Abad and Enrique Aranda and Luis D{\'i}ez and Jaime Feliu and Carlos G{\'o}mez and Antonio Irigoyen and Rafael L{\'o}pez and Fernando Rivera and Carmen Rubio and Javier Sastre and Josep Tabernero and Eduardo D{\'i}az-Rubio",
year = "2009",
month = "5",
doi = "10.1007/s12094-009-0357-3",
language = "English (US)",
volume = "11",
pages = "290--301",
journal = "Clinical and Translational Oncology",
issn = "1699-048X",
publisher = "Springer-Verlag Italia",
number = "5",

}

TY - JOUR

T1 - Consensus on the treatment of pancreatic cancer in Spain

AU - Hidalgo, Manuel

AU - Abad, Albert

AU - Aranda, Enrique

AU - Díez, Luis

AU - Feliu, Jaime

AU - Gómez, Carlos

AU - Irigoyen, Antonio

AU - López, Rafael

AU - Rivera, Fernando

AU - Rubio, Carmen

AU - Sastre, Javier

AU - Tabernero, Josep

AU - Díaz-Rubio, Eduardo

PY - 2009/5

Y1 - 2009/5

N2 - Pancreatic cancer (PC) represents one of the greatest oncological challenges of our century, due to its high mortality and incidence. A group of Spanish experts in PC treatment reviewed data available on different therapeutic combinations and established consensus on what would be the best strategy in PC management, depending on the stage of the disease. Surgery with complete resection may produce 5-year survival rates of 18-24%, but definitive control is still precarious. In the absence of consensus, the best evidence suggests that adjuvant chemotherapy with gemcitabine for 6 months using the CONKO-001 regime is the treatment of choice after resection of PC for patients with acceptable functional status. This group recommends chemoradiotherapy (CT-RT) in patients with factors for poor loco-regional prognosis. However, chemotherapy is an option for the treatment of locally advanced PC in patients with good general status and in the absence of metastatic disease the recommended treatment is CT-RT followed by gemcitabine-based chemotherapy. A period of chemotherapy followed by consolidation CT-RT may be appropriate, as it allows selection of patients with locally advanced disease who may benefit most from combined treatment. Erlotinib combined with gemcitabine shows significant survival improvement in PC and must be considered an option in the first-line treatment of advanced and metastatic PC. The gemcitabine-erlotinib combination is proposed as the standard treatment for metastatic PC in patients with PS≥2. In patients with PS

AB - Pancreatic cancer (PC) represents one of the greatest oncological challenges of our century, due to its high mortality and incidence. A group of Spanish experts in PC treatment reviewed data available on different therapeutic combinations and established consensus on what would be the best strategy in PC management, depending on the stage of the disease. Surgery with complete resection may produce 5-year survival rates of 18-24%, but definitive control is still precarious. In the absence of consensus, the best evidence suggests that adjuvant chemotherapy with gemcitabine for 6 months using the CONKO-001 regime is the treatment of choice after resection of PC for patients with acceptable functional status. This group recommends chemoradiotherapy (CT-RT) in patients with factors for poor loco-regional prognosis. However, chemotherapy is an option for the treatment of locally advanced PC in patients with good general status and in the absence of metastatic disease the recommended treatment is CT-RT followed by gemcitabine-based chemotherapy. A period of chemotherapy followed by consolidation CT-RT may be appropriate, as it allows selection of patients with locally advanced disease who may benefit most from combined treatment. Erlotinib combined with gemcitabine shows significant survival improvement in PC and must be considered an option in the first-line treatment of advanced and metastatic PC. The gemcitabine-erlotinib combination is proposed as the standard treatment for metastatic PC in patients with PS≥2. In patients with PS

KW - Consensus document

KW - Epidermal growth factor receptor inhibitor

KW - Erlotinib

KW - Pancreatic cancer

KW - Spain

UR - http://www.scopus.com/inward/record.url?scp=68849087986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68849087986&partnerID=8YFLogxK

U2 - 10.1007/s12094-009-0357-3

DO - 10.1007/s12094-009-0357-3

M3 - Article

VL - 11

SP - 290

EP - 301

JO - Clinical and Translational Oncology

JF - Clinical and Translational Oncology

SN - 1699-048X

IS - 5

ER -